Molecular and Cellular Biochemistry

, Volume 365, Issue 1–2, pp 233–242

Chronic hydrogen-rich saline treatment reduces oxidative stress and attenuates left ventricular hypertrophy in spontaneous hypertensive rats

Article

Abstract

In hypertensive animals and patients, oxidative stress represents the primary risk factor for progression of left ventricular hypertrophy. Recently, it has been demonstrated that hydrogen, as a novel antioxidant, can selectively reduce hydroxyl radicals and peroxynitrite anion to exert therapeutic antioxidant activity. In the current study, we explored the effect of chronic treatment with hydrogen-rich saline (HRS) on left ventricular hypertrophy in spontaneously hypertensive rats (SHR). The 8-week-old male SHR and age-matched Wistar-Kyoto rats (WKY) were randomized into HRS-treated (6 ml/kg/day for 3 months, i.p.) and vehicle-treated groups. HRS treatment had no significant effect on blood pressure, but it effectively attenuated left ventricular hypertrophy in SHR. HRS treatment abated oxidative stress, restored the activity of antioxidant enzymes including GPx, GST, catalase, and SOD, suppressed NADPH oxidase activity and downregulated Nox2 and Nox4 expression in left ventricles of SHR. HRS treatment suppressed pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and MCP-1, and inhibited NF-κB activation through preventing IκBα degradation in left ventricles of SHR. HRS treatment preserved mitochondrial function through restoring electron transport chain enzyme activity, repressing ROS formation, and enhancing ATP production in left ventricles of SHR. Moreover, HRS treatment suppressed ACE expression and locally reduced angiotensin II generation in left ventricles of SHR. In conclusion, HRS treatment attenuates left ventricular hypertrophy through abating oxidative stress, suppressing inflammatory process, preserving mitochondrial function, in which suppression of HRS on angiotensin II in left ventricles locally might be involved.

Keywords

Hydrogen-rich saline Spontaneously hypertensive rats Oxidative stress Inflammation Mitochondria Angiotensin II 

References

  1. 1.
    Paolisso G, Galzerano D, Gambardella A, Varricchio G, Saccomanno F, D’Amore A, Varricchio M, D’Onofrio F (1995) Left ventricular hypertrophy is associated with a stronger impairment of non-oxidative glucose metabolism in hypertensive patients. Eur J Clin Invest 25:529–533PubMedCrossRefGoogle Scholar
  2. 2.
    Li L, Yi-Ming W, Li ZZ, Zhao L, Yu YS, Li DJ, Xia CY, Liu JG, Su DF (2008) Local RAS and inflammatory factors are involved in cardiovascular hypertrophy in spontaneously hypertensive rats. Pharmacol Res 58:196–201PubMedCrossRefGoogle Scholar
  3. 3.
    Kass DA, Bronzwaer JG, Paulus WJ (2004) What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 94:1533–1542PubMedCrossRefGoogle Scholar
  4. 4.
    Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK (2006) Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci USA 103:7432–7437PubMedCrossRefGoogle Scholar
  5. 5.
    Nadal-Ginard B, Kajstura J, Leri A, Anversa P (2003) Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 92:139–150PubMedCrossRefGoogle Scholar
  6. 6.
    Giordano FJ (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115:500–508PubMedGoogle Scholar
  7. 7.
    Alvarez MC, Caldiz C, Fantinelli JC, Garciarena CD, Console GM, Chiappe de Cingolani GE, Mosca SM (2008) Is cardiac hypertrophy in spontaneously hypertensive rats the cause or the consequence of oxidative stress? Hypertens Res 31:1465–7146PubMedCrossRefGoogle Scholar
  8. 8.
    The Heart Outcomes Prevention Evaluation Study Investigators (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342:154–160CrossRefGoogle Scholar
  9. 9.
    Heart Protection Study Collaborative G (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23–33CrossRefGoogle Scholar
  10. 10.
    Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsura K, Katayama Y, Asoh S, Ohta S (2007) Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 13:688–694PubMedCrossRefGoogle Scholar
  11. 11.
    Maher P, Salgado KF, Zivin JA, Lapchak PA (2007) A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res 1173:117–125PubMedCrossRefGoogle Scholar
  12. 12.
    Ji Q, Hui K, Zhang L, Sun X, Li W, Duan M (2011) The effect of hydrogen-rich saline on the brain of rats with transient ischemia. J Surg Res 168:e95–e101PubMedCrossRefGoogle Scholar
  13. 13.
    Ji X, Liu W, Xie K, Liu W, Qu Y, Chao X, Chen T, Zhou J, Fei Z (2010) Beneficial effects of hydrogen gas in a rat model of traumatic brain injury via reducing oxidative stress. Brain Res 1354:196–205PubMedCrossRefGoogle Scholar
  14. 14.
    Wang F, Yu G, Liu SY, Li JB, Wang JF, Bo LL, Qian LR, Sun XJ, Deng XM (2011) Hydrogen-rich saline protects against renal ischemia/reperfusion injury in rats. J Surg Res 167:e339–e344PubMedCrossRefGoogle Scholar
  15. 15.
    Hayashida K, Sano M, Ohsawa I, Shinmura K, Tamaki K, Kimura K, Endo J, Katayama T, Kawamura A, Kohsaka S, Makino S, Ohta S, Ogawa S, Fukuda K (2008) Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 373:30–35PubMedCrossRefGoogle Scholar
  16. 16.
    Yu YS, Xie HH, Li L, Song SW, Han P, Cai GJ, Su DF (2010) Effects of low-dose ketanserin on atherosclerosis in rats and rabbits. Can J Physiol Pharmacol 88:1054–1060PubMedCrossRefGoogle Scholar
  17. 17.
    Li YL, Gao L, Zucker IH, Schultz HD (2007) NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits. Cardiovasc Res 75:546–554PubMedCrossRefGoogle Scholar
  18. 18.
    Harrison DG, Gongora MC, Guzik TJ, Widder J (2007) Oxidative stress and hypertension. J Am Soc Hypertens 1:30–44PubMedCrossRefGoogle Scholar
  19. 19.
    Elks CM, Mariappan N, Haque M, Guggilam A, Majid DS, Francis J (2009) Chronic NF-κB blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol 296:F298–F305PubMedCrossRefGoogle Scholar
  20. 20.
    Maher P, Salgado KF, Zivin JA, Lapchak PA (2007) A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res 1173:117–125PubMedCrossRefGoogle Scholar
  21. 21.
    Seddon M, Looi YH, Shah AM (2007) Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 93:903–907PubMedCrossRefGoogle Scholar
  22. 22.
    Takimoto E, Kass DA (2007) Role of Oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49:241–248PubMedCrossRefGoogle Scholar
  23. 23.
    Zimmerman MC, Zucker IH (2009) Mitochondrial dysfunction and mitochondrial-produced reactive oxygen species. Hypertension 53:112–114PubMedCrossRefGoogle Scholar
  24. 24.
    Chan SH, Wu KL, Chang AY, Tai MH, Chan JY (2009) Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. Hypertension 53:217–227PubMedCrossRefGoogle Scholar
  25. 25.
    Thomas SR, Witting PK, Drummond GR (2008) Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 10:1713–1765PubMedCrossRefGoogle Scholar
  26. 26.
    Doughan AK, Harrison DG, Dikalov SI (2008) Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 102:488–496PubMedCrossRefGoogle Scholar
  27. 27.
    de Cavanagh EM, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, Fraga CG (2003) Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J 17:1096–1098PubMedGoogle Scholar
  28. 28.
    Zhang Y, Sun Q, He B, Xiao J, Wang Z, Sun X (2011) Anti-inflammatory effect of hydrogen-rich saline in a rat model of regional myocardial ischemia and reperfusion. Int J Cardiol 148:91–95PubMedCrossRefGoogle Scholar
  29. 29.
    Wang C, Li J, Liu Q, Yang R, Zhang JH, Cao YP, Sun XJ (2011) Hydrogen-rich saline reduces oxidative stress and inflammation by inhibit of JNK and NF-κB activation in a rat model of amyloid-beta-induced Alzheimer’s disease. Neurosci Lett 491:127–132PubMedCrossRefGoogle Scholar
  30. 30.
    Kai H, Kuwahara F, Tokuda K, Imaizumi T (2006) Perivascular inflammation and hypertensive cardioavscular remodeling. Curr Hypertens Rev 2:263–269CrossRefGoogle Scholar
  31. 31.
    Janssen-Heininger YMW, Poynter ME, Baeuerle PA (2000) Recent advances towards understanding redox mechanisms in the activation of nuclear factor κB. Free Radic Biol Med 28:1317–1327PubMedCrossRefGoogle Scholar
  32. 32.
    Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 10:2247–2258PubMedGoogle Scholar
  33. 33.
    Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB, Ritchie TC, Hunninghake GW, Zandi E, Engelhardt JF (2001) Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem 276:30188–30198PubMedCrossRefGoogle Scholar
  34. 34.
    Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM (1991) Angiotensin II induces smooth muscle proliferation in the normal and injured rat arterial wall. Circ Res 68:450–456PubMedGoogle Scholar
  35. 35.
    Baker KM, Booz GW, Dostal DE (1992) Cardiac action of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54:227–241PubMedCrossRefGoogle Scholar
  36. 36.
    Sadoshima J, Xu Y, Slayter HS, Izumo S (1993) Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75:977–984PubMedCrossRefGoogle Scholar
  37. 37.
    Weber KT (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96:4065–4082PubMedGoogle Scholar
  38. 38.
    Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS (2000) Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 212:155–169PubMedCrossRefGoogle Scholar
  39. 39.
    Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K, Takeshita A (1997) Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30:1621–1627PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  1. 1.Department of Pharmacology, College of PharmacySecond Military Medical UniversityShanghaiChina
  2. 2.Department of Pharmaceutical Science and Technology, College of Chemistry and BiologyDonghua UniversityShanghaiChina

Personalised recommendations